Online citations, reference lists, and bibliographies.
← Back to Search

Nanoparticle-Based Medicines: A Review Of FDA-Approved Materials And Clinical Trials To Date

Daniel Bobo, K. J. Robinson, Jiaul Islam, K. Thurecht, S. Corrie
Published 2016 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
ABSTRACTIn this review we provide an up to date snapshot of nanomedicines either currently approved by the US FDA, or in the FDA clinical trials process. We define nanomedicines as therapeutic or imaging agents which comprise a nanoparticle in order to control the biodistribution, enhance the efficacy, or otherwise reduce toxicity of a drug or biologic. We identified 51 FDA-approved nanomedicines that met this definition and 77 products in clinical trials, with ~40% of trials listed in clinicaltrials.gov started in 2014 or 2015. While FDA approved materials are heavily weighted to polymeric, liposomal, and nanocrystal formulations, there is a trend towards the development of more complex materials comprising micelles, protein-based NPs, and also the emergence of a variety of inorganic and metallic particles in clinical trials. We then provide an overview of the different material categories represented in our search, highlighting nanomedicines that have either been recently approved, or are already in clinical trials. We conclude with some comments on future perspectives for nanomedicines, which we expect to include more actively-targeted materials, multi-functional materials (“theranostics”) and more complicated materials that blur the boundaries of traditional material categories. A key challenge for researchers, industry, and regulators is how to classify new materials and what additional testing (e.g. safety and toxicity) is required before products become available.
This paper references
10.1517/17425247.2013.758631
Hyperthermia-induced drug targeting
Jonathan P. May (2013)
10.1021/mp900015y
The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic.
M. Davis (2009)
Size dependence of Au NP-enhanced surface plasmon resonance based 2386 Bobo et al. on differential phase measurement
S Zeng (2013)
10.3748/wjg.v21.i47.13400
Current status of superparamagnetic iron oxide contrast agents for liver magnetic resonance imaging.
Y. Wang (2015)
10.1146/annurev-bioeng-071811-150124
The effect of nanoparticle size, shape, and surface chemistry on biological systems.
Alexandre Albanese (2012)
10.1016/S0924-8579(00)00341-1
Lipid-based amphotericin B: a review of the last 10 years of use.
I. Hann (2001)
Magnetite nanoparticles as a single dose treatment for iron deficiency anemia
BakrMM Salah EDTA (2010)
10.1007/s11060-010-0389-0
Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme
K. Maier-Hauff (2010)
10.1021/mp800051m
Factors Affecting the Clearance and Biodistribution of Polymeric Nanoparticles
F. Alexis (2008)
10.1517/14712598.2010.481666
Rexin-G, a targeted genetic medicine for cancer
E. Gordon (2010)
Tumour targeting by enhanced permeability and retention (EPR) effect
R Duncan (1998)
10.1016/j.nano.2012.05.013
The big picture on nanomedicine: the state of investigational and approved nanomedicine products.
M. Etheridge (2013)
Neglected disease research and development: is the global financial crisis changing R&D. London: Policy Cures
P Cures (2011)
10.1016/j.ygyno.2008.04.033
MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer.
D. Taylor (2008)
Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes.
A. Gabizon (1994)
10.1038/mt.2013.32
Phase I study of a systemically delivered p53 nanoparticle in advanced solid tumors.
N. Senzer (2013)
10.1039/C1PY00034A
FDA-approved poly(ethylene glycol)–protein conjugate drugs
Steevens N S Alconcel (2011)
10.1117/12.2032813
Magnetomotive imaging of iron oxide nanoparticles as cellular contrast agents for optical coherence tomography
P. Cimalla (2013)
10.1016/S0022-2836(65)80093-6
Diffusion of univalent ions across the lamellae of swollen phospholipids.
A. Bangham (1965)
KM.Magnetite nanoparticles as a single dose treatment for iron deficiency anemia
Salah EDTA (2010)
10.1021/BM0502720
Novel fast degradable thermosensitive polymeric micelles based on PEG-block-poly(N-(2-hydroxyethyl)methacrylamide-oligolactates).
C. Rijcken (2005)
10.1038/nbt1340
Renal clearance of quantum dots
H. Choi (2007)
10.1097/00006982-200402000-00001
Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynamic therapy report 2.
S. Harding (2001)
10.1002/adma.201104763
Mesoporous silica nanoparticles: synthesis, biocompatibility and drug delivery.
F. Tang (2012)
10.1158/1078-0432.CCR-05-1634
Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel.
N. Desai (2006)
10.1039/C5EN00037H
Gene expression as an indicator of the molecular response and toxicity in the bacterium Shewanella oneidensis and the water flea Daphnia magna exposed to functionalized gold nanoparticles
Tian A Qiu (2015)
10.1038/sj.clpt.6100400
Nanoparticles in Medicine: Therapeutic Applications and Developments
L. Zhang (2008)
10.1002/wnan.1257
What nanomedicine in the clinic right now really forms nanoparticles?
S. Svenson (2014)
10.1016/J.SNB.2012.09.073
Size dependence of Au NP-enhanced surface plasmon resonance based on differential phase measurement
Shuwen Zeng (2013)
10.1039/c2cs15327k
Design of polymeric nanoparticles for biomedical delivery applications.
Mahmoud Elsabahy (2012)
10.1016/J.EURSUP.2005.04.001
Eligard®: Pharmacokinetics, Effect on Testosterone and PSA Levels and Tolerability
R. Berges (2005)
10.1038/mt.2009.228
Advanced Phase I/II Studies of Targeted Gene Delivery In Vivo: Intravenous Rexin-G for Gemcitabine-resistant Metastatic Pancreatic Cancer
S. Chawla (2010)
10.1002/CHIN.201227268
The Golden Age: Gold Nanoparticles for Biomedicine
Erik C Dreaden (2012)
10.1021/nn201950e
Nanoparticle size is a critical physicochemical determinant of the human blood plasma corona: a comprehensive quantitative proteomic analysis.
S. Tenzer (2011)
J Control Release
(2011)
Sirolimus. AY 22989, NSC 226080, NSC 606698, rapamycin, Rapamune.
(1999)
10.1155/2015/123756
Denileukin Diftitox (Ontak) as Maintenance Therapy for Peripheral T-Cell Lymphomas: Three Cases with Sustained Remission
A. C. Fuentes (2015)
10.1186/1743-8977-4-10
Kupffer cells are central in the removal of nanoparticles from the organism
E. Sadauskas (2007)
10.1038/nmat2442
Understanding biophysicochemical interactions at the nano-bio interface.
A. Nel (2009)
Toxicological considerations of clinically applicable nanoparticles
L. Yildirimer (2011)
10.1021/cr100449n
Core/shell nanoparticles: classes, properties, synthesis mechanisms, characterization, and applications.
Rajib Ghosh Chaudhuri (2012)
10.1158/1078-0432.CCR-10-0978
Phase I and Pharmacokinetic Studies of CYT-6091, a Novel PEGylated Colloidal Gold-rhTNF Nanomedicine
S. Libutti (2010)
10.1016/j.cellimm.2015.12.006
Immunogenicity of long-lasting recombinant factor VIII products.
M. Ing (2016)
10.1016/j.nano.2015.07.015
Design considerations for nanotherapeutics in oncology.
T. Stylianopoulos (2015)
10.3978/j.issn.2223-4292.2011.08.03
Superparamagnetic iron oxide based MRI contrast agents: Current status of clinical application.
Y. Wáng (2011)
10.1016/j.jconrel.2014.05.001
Polymer therapeutics: Top 10 selling pharmaceuticals - what next?
R. Duncan (2014)
10.1016/S0002-9394(01)01237-5
Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy report 2.
N. Bressler (2002)
10.1080/14737140.2016.1174581
Nanoliposomal irinotecan plus fluorouracil and folinic acid: a new treatment option in metastatic pancreatic cancer
Sana Saif Ur Rehman (2016)
10.1021/ja410351h
Multimodal polymer nanoparticles with combined 19F magnetic resonance and optical detection for tunable, targeted, multimodal imaging in vivo.
B. Rolfe (2014)
10.1089/rej.2011.1305
Plasmonic photothermic and stem cell therapy of atherosclerotic plaque as a novel nanotool for angioplasty and artery remodeling.
A. Kharlamov (2012)
10.1007/s11095-010-0233-4
Polymeric Micelles in Anticancer Therapy: Targeting, Imaging and Triggered Release
C. Oerlemans (2010)
10.1038/nbt.3330
Principles of nanoparticle design for overcoming biological barriers to drug delivery
E. Blanco (2015)
10.1021/ja100252y
Functional hyperbranched polymers: toward targeted in vivo 19F magnetic resonance imaging using designed macromolecules.
K. Thurecht (2010)
10.1016/J.NANTOD.2011.10.001
Toxicology and clinical potential of nanoparticles
L. Yildirimer (2011)
10.1166/JNN.2006.480
New method for the effective production of ultrafine drug nanocrystals.
J. Möschwitzer (2006)
10.1093/ANNONC/MDL104
Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer.
M. Green (2006)
10.1016/j.jconrel.2011.03.007
Preclinical to clinical development of the novel camptothecin nanopharmaceutical CRLX101.
Sonke Svenson (2011)
10.7150/thno.9404
Nanoparticle-Mediated Systemic Delivery of siRNA for Treatment of Cancers and Viral Infections
M. Draz (2014)
10.1002/CHIN.201007253
Soluble Polymer Carriers for the Treatment of Cancer: The Importance of Molecular Architecture
Megan E. Fox (2010)
10.1126/scitranslmed.3009524
Clinical translation of an ultrasmall inorganic optical-PET imaging nanoparticle probe
Evan Phillips (2014)
10.3109/10428194.2012.742521
A multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: the CONCEPT study
F. Foss (2013)
10.1126/scitranslmed.3003651
Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile
Jeffrey Hrkach (2012)
10.1039/c2cs15344k
Targeted polymeric therapeutic nanoparticles: design, development and clinical translation.
Nazila Kamaly (2012)
The impact of the European financial crisis on clinical research within the European union or "when life gives you lemons, make lemonade".
G. Tsoulfas (2012)
10.1016/j.addr.2012.06.006
Nanotheranostics for personalized medicine.
S. Mura (2012)
Neglected disease research and development: is the global financial crisis changing R&D
P. Cures (2011)
10.1038/nnano.2015.341
Long-term monitoring for nanomedicine implants and drugs.
M. Kendall (2016)
10.1002/IJC.2910510618
Therapy of primary and metastatic mouse mammary carcinomas with doxorubicin encapsulated in long circulating liposomes
J. Vaage (1992)
10.1186/1748-717X-9-150
Hafnium oxide nanoparticles: toward an in vitro predictive biological effect?
Julie Marill (2014)
10.1002/jmri.24691
Emerging applications for ferumoxytol as a contrast agent in MRI
M. Bashir (2015)
10.2217/nnm.13.8
Therapeutic nanoparticles in clinics and under clinical evaluation.
Catherine A. Schütz (2013)
Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second - line treatment of non - small - cell lung can
L Paz-Ares (2008)
10.1016/S1470-2045(13)70429-7
Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study.
A. Awada (2013)
10.1016/j.cis.2013.10.012
Emerging methods for the fabrication of polymer capsules.
J. Cui (2014)
10.1093/ANNONC/9.SUPPL_5.S39
Lymphocyte predominant Hodgkin's disease: pathology and clinical implication.
J. Franklin (1998)
10.1021/mp800049w
Pharmacokinetics and biodistribution of nanoparticles.
Shyh-Dar Li (2008)
10.1016/j.ijpharm.2010.07.044
Nanocrystals: industrially feasible multifunctional formulation technology for poorly soluble actives.
R. Shegokar (2010)
10.2217/nnm.11.79
In vivo biodistribution of nanoparticles.
Joao Paulo Mattos Almeida (2011)
10.1016/j.jconrel.2015.08.056
Pre-clinical immunotoxicity studies of nanotechnology-formulated drugs: Challenges, considerations and strategy.
M. Dobrovolskaia (2015)
10.1016/j.jconrel.2012.01.026
Antibody-drug conjugates: basic concepts, examples and future perspectives.
G. Casi (2012)
New use of metals as nanosized radioenhancers.
A. Pottier (2014)
10.1002/CHIN.201227277
Targeted Polymeric Therapeutic Nanoparticles: Design, Development and Clinical Translation
Nazila Kamaly (2012)
A novel PEGylated interferon Beta-1a for multiple sclerosis: safety, Nanomedicines - Approved Products and Clinical Trials 2385 pharmacology, and biology
X Hu (2012)
10.1126/scitranslmed.aad2355
Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo
S. Ashton (2016)
A review of controlled clinical trials examining the effects of antimalarial compounds and gold compounds on radiographic progression in rheumatoid arthritis.
M. Sanders (2000)
10.1093/CID/CIU792
Biotechnology and Biopharmaceuticals: Transforming Proteins and Genes Into Drugs, 2nd Edition
Doris M. Benbrook (2014)
10.1016/S0936-6555(05)80269-9
Liposomal doxorubicin (Doxil): an effective new treatment for Kaposi's sarcoma in AIDS.
N. James (1994)
10.1016/s0002-9394(01)00967-9
Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy report 2.
N. Bressler (2002)
10.1212/wnl.50.3.701
Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. 1998 [classical article].
K. Johnson (2001)
10.1038/sj.bjc.6604372
Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer
L. Paz-Ares (2008)
Magnetite nanoparticles as a single dose treatment for iron deficiency anemia. Google Patents
Edta Salah (2010)
10.2147/IJN.S595
Nanocrystal technology, drug delivery and clinical applications
Jens-Uwe A. H. Junghanns (2008)
10.1039/c5nr01050k
Silica-gold nanoparticles for atheroprotective management of plaques: results of the NANOM-FIM trial.
A. Kharlamov (2015)
10.1053/J.SEMINONCOL.2005.12.017
Clinical experience with denileukin diftitox (ONTAK).
F. Foss (2006)
Novel fas t degradable thermosensitive polymeric micelles based on PEG-blockpoly(N-(2-hydroxyethyl)methacrylamide-oligolactates). Biomacromolecules
CJF Rijcken (2005)
10.1111/nyas.12403
Nanomedicines: addressing the scientific and regulatory gap
S. Tinkle (2014)
Semin Oncol
(2006)
10.1371/journal.pone.0096584
Size-Dependent Effects of Gold Nanoparticles Uptake on Maturation and Antitumor Functions of Human Dendritic Cells In Vitro
S. Tomić (2014)
10.1177/0091270011407068
A Novel PEGylated Interferon Beta‐1a for Multiple Sclerosis: Safety, Pharmacology, and Biology
X. Hu (2012)
10.1038/bjc.2015.435
Antibody-drug conjugates—an emerging class of cancer treatment
N. Diamantis (2016)
10.3892/ol.2014.2449
A dual-targeting liposome conjugated with transferrin and arginine-glycine-aspartic acid peptide for glioma-targeting therapy
L. Qin (2014)
10.1016/S0140-6736(15)00986-1
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial
A. Wang-Gillam (2016)
Preclinical to c l i n i c a l d e v e l o pmen t o f t h e no v e l c amp t o t h e c i n nanopharmaceutical CRLX101
S Svenson (2011)
10.1016/j.addr.2012.09.037
Liposomal drug delivery systems: from concept to clinical applications.
T. Allen (2013)
10.1007/978-1-61779-052-2_21
Nanoparticle therapeutics: FDA approval, clinical trials, regulatory pathways, and case study.
Aaron C. Eifler (2011)
10.1080/02656730802104757
Clinical applications of magnetic nanoparticles for hyperthermia
B. Thiesen (2008)



This paper is referenced by
10.7150/thno.30977
Convection-Enhanced Delivery of a Virus-Like Nanotherapeutic Agent with Dual-Modal Imaging for Besiegement and Eradication of Brain Tumors
Hao-Han Pang (2019)
10.3389/fphys.2017.00508
Inhibition of Toll-Like Receptor Signaling as a Promising Therapy for Inflammatory Diseases: A Journey from Molecular to Nano Therapeutics
Wei Gao (2017)
10.3390/jimaging4010018
Image-Guided Cancer Nanomedicine
D. Kim (2018)
10.1021/acsnano.7b01026
Designing Liposomes To Suppress Extracellular Matrix Expression To Enhance Drug Penetration and Pancreatic Tumor Therapy.
T. Ji (2017)
10.1101/817296
Sex-dependent macromolecule and nanoparticle delivery in experimental brain injury
Vimala N. Bharadwaj (2019)
10.2174/1389200221666200103091753
Nanotechnology-Based Drug Delivery, Metabolism and Toxicity.
Pooja Malaviya (2020)
10.20900/mo.20190021
Engineering Tumor-Targeting Nanoparticles as Vehicles for Precision Nanomedicine
Amber Gonda (2019)
10.1038/s41573-018-0006-z
Delivery technologies for cancer immunotherapy
Rachel S Riley (2019)
10.1016/j.ejps.2018.11.019
Nanomedicines: The magic bullets reaching their target?
B. Flühmann (2019)
10.1016/j.smaim.2020.04.001
Nanoparticle-based drug delivery systems for cancer therapy
Yu Dang (2020)
10.1016/j.biomaterials.2019.119464
Engineered nano-immunopotentiators efficiently promote cancer immunotherapy for inhibiting and preventing lung metastasis of melanoma.
Lijia Luo (2019)
10.3390/nano10040789
Emerging Nano- and Micro-Technologies Used in the Treatment of Type-1 Diabetes
Rosita Primavera (2020)
10.4081/MICROSCOPIE.2017.6732
Microscopy techniques in nanomedical research
M. Costanzo (2017)
10.1016/j.ijpharm.2018.05.045
Poly (amidoamine) (PAMAM) dendrimer mediated delivery of drug and pDNA/siRNA for cancer therapy.
Jun Li (2018)
10.3390/antibiotics8040260
The Use of Nanomedicine for Targeted Therapy against Bacterial Infections
Abdulkader Masri (2019)
10.2147/IJN.S249622
Size-Dependent Interactions of Lipid-Coated Gold Nanoparticles: Developing a Better Mechanistic Understanding Through Model Cell Membranes and in vivo Toxicity
Arek M. Engstrom (2020)
10.1016/j.jiec.2020.03.026
Enhanced chitin gel with magnetic nanofiller for lysozyme purification
Gabriel Ibrahin Tovar (2020)
10.5812/ans.98722
Mesenchymal Cell-Derived Exosomes as Novel Useful Candidates for Drug Delivery
Masoumeh Einabadi (2020)
10.1039/c7cs00680b
The development of ruthenium(ii) polypyridyl complexes and conjugates for in vitro cellular and in vivo applications.
Fergus E. Poynton (2017)
10.1016/j.jare.2018.06.005
Smart nanocarrier-based drug delivery systems for cancer therapy and toxicity studies: A review
S. Hossen (2019)
10.1590/1980-5373-MR-2018-0074
Process Evaluation of Sugar-Based Polymeric Colloidal Nanocarrier Formation
Thais Aragão Horoiwa (2019)
10.5897/SRE2019.6604
Nanomedicines: Challenges and perspectives for future nanotechnology in the healthcare system
Ajazuddin (2019)
Optimizing the Physical Properties of Vascular Targeted Carriers for Maximum Efficacy in Inflammatory Disease
M. Fish (2018)
10.1007/s11095-018-2380-y
Simulation of Stimuli-Responsive and Stoichiometrically Controlled Release Rate of Doxorubicin from Liposomes in Tumor Interstitial Fluid
E. Yamamoto (2018)
10.1039/c9nr09683c
Biocompatibility assessment of sub-5 nm silica-coated superparamagnetic iron oxide nanoparticles in human stem cells and in mice for potential application in nanomedicine.
M. Ledda (2020)
10.1002/anie.201903256
Tuning the In Vivo Transport of Anticancer Drugs Using Renal-Clearable Gold Nanoparticles.
Chuanqi Peng (2019)
10.3390/ma12101588
Nanotechnology Meets Oncology: Nanomaterials in Brain Cancer Research, Diagnosis and Therapy
Alja Zottel (2019)
10.1021/acs.bioconjchem.7b00664
Ultrasmall-in-Nano Approach: Enabling the Translation of Metal Nanomaterials to Clinics.
D. Cassano (2018)
10.1002/MAME.201800146
High-throughput miniaturized screening of nanoparticle formation via inkjet printing
I. D. Styliari (2018)
10.2147/IJN.S168053
Recent advances in “smart” delivery systems for extended drug release in cancer therapy
Regina-Veronicka Kalaydina (2018)
10.1007/s11064-018-2598-4
How to Study the Uptake and Toxicity of Nanoparticles in Cultured Brain Cells: The Dos and Don’t Forgets
Wiebke Willmann (2018)
10.1016/J.MSEC.2019.05.017
TPGS-grafted and acid-responsive soy protein nanogels for efficient intracellular drug release, accumulation, penetration in 3D tumor spheroids of drug-resistant cancer cells.
X. Cheng (2019)
See more
Semantic Scholar Logo Some data provided by SemanticScholar